The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNXP | +22.21% | -100% | -86.5% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +409% |
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
A spot of potentially good news can't stop the investor exodus from the biotech stock.
The sell-off that began on Monday continues.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.29M | 16.6% |
| Gross Profit | $1.46M | 90.6% |
| Gross Margin | 44.44% | 17.3% |
| Market Cap | $211.78M | 816.4% |
| Market Cap / Employee | $2.61M | 0.0% |
| Employees | 81 | -21.4% |
| Net Income | -$32.01M | -125.2% |
| EBITDA | -$32.61M | -116.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $190.06M | 573.2% |
| Accounts Receivable | $5.15M | -8.7% |
| Inventory | 5.7 | -30.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.27M | -95.2% |
| Short Term Debt | $0.16M | -94.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.12% | 58.3% |
| Return On Invested Capital | -69.15% | 42.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31.48M | -56.8% |
| Operating Free Cash Flow | -$30.47M | -51.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.01 | 0.56 | 1.37 | 1.09 | 248.49% |
| Price to Sales | 0.07 | 10.55 | 26.82 | 20.93 | 2461.90% |
| Price to Tangible Book Value | 69.28 | 0.56 | 1.37 | 1.09 | -68.77% |
| Enterprise Value to EBITDA | 4.09 | 1.62 | -4.99 | -0.80 | -216.12% |
| Return on Equity | -106.1% | -91.4% | -77.5% | -65.0% | -53.14% |
| Total Debt | $8.12M | $0.56M | $0.49M | $0.43M | -95.11% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
